Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DO-01)

Active:	Yes
Cancer Type:	Ovarian Cancer	NCT ID:	NCT06819007
Trial Phases:	Phase III	Protocol IDs:	DS8201-772 (primary) ENGOT-ov89 ( Other Grant/Funding Number ) (OTHER_G GEICO144-O ( Other Grant/Funding Number ) (OTHER_G GOG-3112 ( Other Grant/Funding Number ) (OTHER_GRA
Eligibility:	, Female	Study Type:	Treatment
Study Sponsor:	Daiichi Sankyo
NCI Full Details:	https://clinicaltrials.gov/study/NCT06819007

Summary

This clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2 (HER2)-expressing (immunohistochemistry [IHC] 3+/2+/1+) advanced high-grade epithelial ovarian cancer.

Objectives

A non-randomized safety run-in phase will be conducted prior to randomization phase to assess the safety of T-DXd in combination with bevacizumab.

Treatment Sites in Georgia

Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
225 Candler Drive
Savannah, GA 31405
912-819-5778
www.sjchs.org

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.